CA2057456C - Anti depression pharmaceutical - Google Patents
Anti depression pharmaceuticalInfo
- Publication number
- CA2057456C CA2057456C CA002057456A CA2057456A CA2057456C CA 2057456 C CA2057456 C CA 2057456C CA 002057456 A CA002057456 A CA 002057456A CA 2057456 A CA2057456 A CA 2057456A CA 2057456 C CA2057456 C CA 2057456C
- Authority
- CA
- Canada
- Prior art keywords
- weeks
- adenine
- dinucleotide
- nicotinamide
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 28
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 claims abstract description 12
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims abstract description 11
- 229950006238 nadide Drugs 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 208000020401 Depressive disease Diseases 0.000 claims abstract description 7
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 9
- 230000003442 weekly effect Effects 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101100450307 Escherichia coli (strain K12) hdfR gene Proteins 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4100361.6 | 1991-01-04 | ||
| DE4100361A DE4100361C1 (enrdf_load_stackoverflow) | 1991-01-04 | 1991-01-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2057456A1 CA2057456A1 (en) | 1992-07-05 |
| CA2057456C true CA2057456C (en) | 1996-02-06 |
Family
ID=6422686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002057456A Expired - Fee Related CA2057456C (en) | 1991-01-04 | 1991-12-10 | Anti depression pharmaceutical |
Country Status (15)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2167104A1 (en) * | 1995-01-17 | 1996-07-18 | Joerg G.D. Birkmayer | Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration |
| US5712259A (en) * | 1996-04-22 | 1998-01-27 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome |
| US5668114A (en) * | 1996-05-08 | 1997-09-16 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating hypertension |
| ES2953842B2 (es) * | 2023-07-17 | 2025-02-14 | Nuadi Europe S L | Tapacubos antipolvo |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3341412A (en) * | 1966-03-04 | 1967-09-12 | Enzomedic Lab Inc | Methods of treating schizophrenia |
| US4970200A (en) * | 1988-03-01 | 1990-11-13 | Schering Aktiengesellschaft | Agent for treatment of Parkinson's disease |
-
1991
- 1991-01-04 DE DE4100361A patent/DE4100361C1/de not_active Expired - Lifetime
- 1991-11-07 EP EP91250304A patent/EP0493861B1/de not_active Expired - Lifetime
- 1991-11-07 ES ES91250304T patent/ES2097181T3/es not_active Expired - Lifetime
- 1991-11-07 AT AT91250304T patent/ATE148991T1/de not_active IP Right Cessation
- 1991-11-07 DK DK91250304.2T patent/DK0493861T3/da active
- 1991-11-07 DE DE59108553T patent/DE59108553D1/de not_active Expired - Fee Related
- 1991-11-28 BR BR919105183A patent/BR9105183A/pt not_active Application Discontinuation
- 1991-12-10 CA CA002057456A patent/CA2057456C/en not_active Expired - Fee Related
- 1991-12-20 IE IE447791A patent/IE914477A1/en not_active IP Right Cessation
- 1991-12-27 JP JP3346474A patent/JP2519148B2/ja not_active Expired - Fee Related
- 1991-12-31 AU AU90109/91A patent/AU631755B2/en not_active Ceased
-
1992
- 1992-01-02 PT PT99962A patent/PT99962B/pt not_active IP Right Cessation
- 1992-01-03 ZA ZA9244A patent/ZA9244B/xx unknown
- 1992-01-03 NO NO920056A patent/NO179602C/no not_active IP Right Cessation
- 1992-01-03 HU HU9200025A patent/HU213112B/hu not_active IP Right Cessation
-
1997
- 1997-03-03 GR GR970400414T patent/GR3022724T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9105183A (pt) | 1992-09-29 |
| NO920056D0 (no) | 1992-01-03 |
| JP2519148B2 (ja) | 1996-07-31 |
| EP0493861A3 (en) | 1993-03-03 |
| JPH05139978A (ja) | 1993-06-08 |
| DE59108553D1 (de) | 1997-03-27 |
| NO920056L (no) | 1992-07-06 |
| PT99962A (pt) | 1993-02-26 |
| NO179602C (no) | 1996-11-13 |
| AU9010991A (en) | 1992-07-16 |
| HU213112B (en) | 1997-02-28 |
| ZA9244B (en) | 1992-10-28 |
| HUT60141A (en) | 1992-08-28 |
| EP0493861A2 (de) | 1992-07-08 |
| GR3022724T3 (en) | 1997-06-30 |
| IE914477A1 (en) | 1992-07-15 |
| EP0493861B1 (de) | 1997-02-19 |
| CA2057456A1 (en) | 1992-07-05 |
| NO179602B (no) | 1996-08-05 |
| DE4100361C1 (enrdf_load_stackoverflow) | 1992-04-23 |
| PT99962B (pt) | 1999-06-30 |
| DK0493861T3 (da) | 1997-08-25 |
| ATE148991T1 (de) | 1997-03-15 |
| AU631755B2 (en) | 1992-12-03 |
| HU9200025D0 (en) | 1992-03-30 |
| ES2097181T3 (es) | 1997-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cairncross et al. | Olfactory projection systems, drugs and behaviour: a review | |
| Thomas et al. | The in vitro fungicidal properties of Visco‐gel, alone and combined with nystatin and amphotericin B | |
| Shults | Coenzyme Q10 in neurodegenerative diseases | |
| JP2008260782A (ja) | 神経細胞機能の維持、その消失の防止又は回復のためのデプレニル化合部を利用した器具 | |
| CA2057456C (en) | Anti depression pharmaceutical | |
| US4735968A (en) | Method of treating tinnitus with AOAA | |
| Zimmermann et al. | The impact of diets with different magnesium contents on magnesium and calcium in serum and tissues of the rat | |
| US6727288B2 (en) | Method for treating bone fracture | |
| US20210369699A1 (en) | Treatment of lupus erythematosus using s-hydroxychloroquine | |
| Sangdee et al. | Enhancement of central norepinephrine and 5-hydroxytryptamine transmission by tricyclic antidepressants: a comparison | |
| CN110225767A (zh) | 细胞内atp增强剂 | |
| Bieck et al. | Monoamine oxidase inhibition by tranylcypromine: assessment in human volunteers | |
| Goyer et al. | Mood-altering effects of disulfiram in alcoholics. | |
| Hutchison et al. | The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia | |
| Elwes et al. | Treatment of narcolepsy with L-tyrosine: double-blind placebo-controlled trial | |
| Daune‐Anglard et al. | Some biochemical and pathophysiological aspects of long‐term elevation of brain ornithine concentrations | |
| US20070082903A1 (en) | Remedy for rheumatoid arthritis | |
| EP0087744B1 (en) | Lipid metabolism improving agents | |
| CN1145481C (zh) | 噻唑烷酮在制备用于治疗和预防神经变性疾病药物的用途 | |
| EP0005733A1 (en) | Pharmaceutical compositions for use in the treatment of diabetic nephropathy and method for preparing them | |
| Montgomery et al. | Acetohexamide in treatment of diabetes mellitus | |
| Gastpar et al. | Befuraline, its safety and efficacy in depressed inpatients | |
| RU2161011C1 (ru) | Способ выбора индивидуального лечения больных, страдающих бронхиальной астмой | |
| Urivetzky et al. | Absence of effect of allopurinol on oxalate excretion by stone patients on random and controlled diets | |
| WO2001007041A1 (fr) | Medicament anti-arythmique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |